openPR Logo
Press release

Human Papillomavirus Infections Vaccine Pipeline Analysis

06-30-2017 09:12 AM CET | Health & Medicine

Press release from: PNS Pharma

Human Papillomavirus Infections Vaccine Pipeline Analysis

Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an “ideal” vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way.

The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs).

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Human-Papillomavirus-Infections-Pipeline-Analysis

Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines.

“Human Papillomavirus Infections Vaccine Pipeline Analysis” Report Highlights:

• Human Papillomavirus Vaccine Market Overview
• Marketed Drug Profiles & Patent Analysis
• Clinical Trial Insight by Phase & Country
• Drug Clinical Development Phase: 47
• Suspended & Discontinued Drug Profiles: 46
• Competitive Landscape

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Human Papillomavirus Infections Vaccine Pipeline Analysis here

News-ID: 603229 • Views:

More Releases from PNS Pharma

Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight: o Global Gene Therapy Market Opportunity: > US$ 8 Billion o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials o Commercially Available Gene Therapies: 11 o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials o Cancer Accounts For 50% of Global Gene Therapy Trials Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026 Over the years, gene therapy has been highly responsible for decreasing the mortality rate
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria

All 5 Releases


More Releases for HPV

Human Papillomavirus (HPV) Vaccines Market is Thriving Worldwide with Top Compan …
Los Angeles, United State, –The report titled Global Human Papillomavirus (HPV) Vaccines Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Human Papillomavirus (HPV) Vaccines market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete
HPV Vaccines Market 2020-2026 - COVID19 Impact On HPV Vaccines Industry | Top Ke …
HPV Vaccines Market Size, Share & Industry Analysis, By Type (Bivalent and Polyvalent), By Disease Indication (HPV Associated Cancer and Genital Warts), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) and Geography Forecast, 2019-2026. Get Sample Copy Of Report To Know The Impact of Covid19 on this Industry: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-papillomavirus-hpv-vaccines-market-101962 Top Key Players: GSK, Merck. An Overview of the Impact of COVID-19 on HPV Vaccines Market: The emergence of COVID-19 has brought
HPV Testing & PAP Test Market by Test Type (HPV Testing, Follow-up HPV Testing, …
Global HPV Testing & PAP Test Market was valued at USD XX billion in the year 2017. Global HPV Testing & PAP Test market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX billion by the year 2023. Get Free Access to Sample Report @ https://genesismarketinsights.com/Sample_Request/GENRE385 In the Global HPV Testing & PAP Test Market, by region, North America holds the highest market share
Human Papillomavirus (HPV) Therapeutics Market to Reach US$2.34 bn by 2020, Driv …
Human papillomavirus (HPV) and cytomegalovirus (CMV) are viral pathogens affecting individuals of all ages. HPV causes serious sexually transmitted diseases (STDs), while CMV is an opportunistic pathogen affecting immunocompromised individuals such as HIV patients. The global market for HPV and CMV therapeutics is expected to experience a surge due to various macro and micro economic factors. Read the Comprehensive Overview of Human Papillomavirus (HPV) Therapeutics Market:
Cytology and HPV Testing Market: Disparate Levels of Awareness among Patients Re …
Over the years, the level of awareness among the global population regarding the various types of cancer has increased tremendously. The significance of early detection and diagnosis is not lost on them, resulting in the increased adoption of screening tests such as cytology and human papillomavirus (HPV) testing. The global market for cytology and HPV testing is presented with a host of sustained growth opportunities arising mainly from several emerging economies,
New Research: Global Human Papillomavirus (HPV) Market
MarketResearchReports.Biz presents this most up-to-date research on "Human Papillomavirus (HPV)- Epidemiology Forecast To 2023" Latest Report, Human Papillomavirus (HPV) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Human Papillomavirus (HPV) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Human Papillomavirus (HPV) prevalent or incident cases segmented by age, sex and subpopulations. The